Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF managed by Southern Fund experienced a decline of 0.69% on November 11, with a trading volume of 819.30 million yuan, indicating a challenging market environment for innovative drug investments [1] Group 1: Fund Performance - The fund's total shares increased by 75 million, bringing the latest total to 1.568 billion shares, with an increase of 818 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 1.355 billion yuan [1] - Since its establishment on September 12, 2025, the fund has reported a return of -13.60%, while the return over the past month is -8.36% [1] Group 2: Management and Benchmark - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] - The performance benchmark for the fund is the Guozhen Hong Kong Stock Connect Innovative Drug Index, adjusted for valuation exchange rates [1]
11月11日港股通创新药ETF南方（159297）份额增加7500.00万份
Xin Lang Cai Jing·2025-11-12 01:11